title: A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.
abstract: BACKGROUND
  The optimal schedule of taxane administration has been an area of active interest in several recent clinical trials.
  
  
  METHODS
  To address a pure schedule question, we randomized 161 patients with advanced stage IIIB or IV non-small-cell lung cancer (NSCLC) to either paclitaxel 225 mg/m2 every 3 weeks x 4 cycles or 75 mg/m2/week x 12 (cumulative dose on each arm = 900 mg/m2). Both arms received concurrent carboplatin AUC 6 every 3 weeks x 4 cycles.
  
  
  RESULTS
  The two arms were well-balanced in terms of known prognostic factors. The overall response rate and survival outcomes were similar on the two arms. There was significantly more grade 3/4 thrombocytopenia and grade 2-4 anemia on the weekly arm but less severe myalgias/arthralgias and alopecia. No difference in the rates of peripheral neuropathy was observed; however, patients on the every 3 weeks arm reported significantly more taxane therapy-related side-effects on the functional assessment of cancer therapy taxane subscale.
  
  
  CONCLUSIONS
  This randomized trial exploring schedule-related issues with carboplatin/paclitaxel confirms the versatility of this regimen.
authors.affiliation: Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. socinski@med.unc.edu
authors.forename: M A
authors.initials: MA
authors.lastname: Socinski
authors.forename: A
authors.initials: A
authors.lastname: Ivanova
authors.forename: K
authors.initials: K
authors.lastname: Bakri
authors.forename: J
authors.initials: J
authors.lastname: Wall
authors.forename: M Q
authors.initials: MQ
authors.lastname: Baggstrom
authors.forename: T A
authors.initials: TA
authors.lastname: Hensing
authors.forename: A
authors.initials: A
authors.lastname: Mears
authors.forename: M
authors.initials: M
authors.lastname: Tynan
authors.forename: J
authors.initials: J
authors.lastname: Beaumont
authors.forename: A H
authors.initials: AH
authors.lastname: Peterman
authors.forename: H B
authors.initials: HB
authors.lastname: Niell
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D011446:Prospective Studies; D011788:Quality of Life; D015996:Survival Rate
chemical_list: D016190:Carboplatin; D017239:Paclitaxel